尿液核基质蛋白22检测在膀胱癌诊断中的临床应用  

Clinical application of urine nuclear matrix protein 22 in the diagnosis of bladder cancer

作　　者：周巍[1] ZHOU Wei(Department of Clinical Laboratory,Erdos Central Hospital in Inner Mongolia,Erdos 017000,China)

机构地区：[1]内蒙古自治区鄂尔多斯市中心医院检验科,内蒙古鄂尔多斯017000

出　　处：《中国现代医生》2018年第16期132-134,共3页China Modern Doctor

摘　　要：目的通过检测尿液中的核基质蛋白22,探讨其在膀胱癌筛查中的临床应用价值。方法收集2017年6~12月在我院就诊的189例可疑膀胱癌患者的尿液标本,对其进行尿液核基质蛋白22检测与尿液脱落细胞学检查,比较这两种检查方法对膀胱癌的诊断结果。结果尿液核基质蛋白22和脱落细胞学检测的敏感性分别为80.0%和57.6%,特异性分别为40.4%和94.2%,两组敏感性和特异性比较差异均有统计学意义(P<0.05)。且两种检查方法对膀胱癌的阳性预测率分别为68.8%和29.1%,两者比较差异显著。结论尿液核基质蛋白22作为新的标记物在临床应用中对患者创伤性较小、敏感度较高,在膀胱癌的诊断中与尿脱落细胞结合筛查可作为首选方法。Objective To investigate the clinical value of detecting nuclear matrix protein 22 in urine in the screening of bladder cancer.Methods Urine samples of 189 suspected bladder cancer patients who were treated in our hospital from June 2017 to December 2017 were collected.We performed urinary nuclear matrix protein 22 test and urine exfoliated cytology test to the urine samples.The diagnostic results of bladder cancer of the two tests were compared.Results The sensitivities of urinary nuclear matrix protein 22 and exfoliative cytology were 80.0%and 57.6%,and the specificities were 40.4%and 94.2%,respectively.There were significant differences in sensitivity and specificity between the two groups(P<0.05).The positive predictive rates of the two methods for bladder cancer were 68.8%and 29.1%,respectively,with significant difference between the two methods.Conclusion Urine nuclear matrix protein 22 as a new marker is less invasive and has high sensitivity in the diagnosis of bladder cancer.Urine nuclear matrix protein 22 combined with exfoliative cytology may be the preferred method in clinic.

关 键 词：膀胱癌 尿液核基质蛋白22 脱落细胞学 敏感性 特异性 

分 类 号：R737.14[医药卫生—肿瘤]